The assay of 1alpha,25-dihydroxyvitamin D3: physiologic and pathologic modulation of circulating hormone levels.

Mark R Haussler, D. J. Baylink, M. R. Hughes, P. F. Brumbaugh, J. E. Wergedal, F. H. Shen, R. L. Nielsen, S. J. Counts, K. M. Bursac, T. A. McCain

Research output: Contribution to journalArticle

135 Citations (Scopus)

Abstract

A sensitive radioreceptor assay for 1alpha,25-dihydroxyvitamin D3 (1alpha,25-(OH)2D3) is utilized to quantitate the circulating concentration of this sterol in experimental animals and humans. When weanling rats are grown for 2 weeks on low calcium or low phosphate diets, limited availability of either ion elicits a five-fold increase in the plasma level of 1alpha,25-(OH)2D3. The enhancement of 1alpha,25-(OH)2D3 in calcium deficiency is dependent upon the presence of the parathyroid and/or thyroid glands, which is consistent with parathyroid hormone (PTH) mediation of this effect. In contrast, the response to phosphate deficiency is independent of these glands and may result from a direct action of low phosphate on the renal synthesis of 1alpha,25-(OH)2D3. Studies in humans indicate that the normal level of 1alpha,25-(OH)2D is 2.1--4.5 ng/100 ml plasma. Patients with chronic renal failure have markedly lower circulating 1alpha,25-(OH)2D and this kidney hormone is undetectable in anephric subjects, but returns to normal within 1 day after successful renal transplantation. Hypoparathyroidism and pseudohypoparathyroidism are associated with reduced plasma 1alpha,25-(OH)2D while patients with primary hyperparathyroidism have significantly elevated sterol hormone levels. Thus, from measurements in rats and humans, it appears that circulating 1alpha,25-(OH)2D3 is regulated by PTH and/or phosphate and that abnormal plasma 1alpha,25-(OH)2D3 is a part of the pathophysiology of renal osteodystrophy and parathyroid disorders.

Original languageEnglish (US)
JournalClinical Endocrinology
Volume5 Suppl
StatePublished - 1976

Fingerprint

Phosphates
Hormones
Sterols
Parathyroid Hormone
Parathyroid Diseases
Pseudohypoparathyroidism
Chronic Kidney Disease-Mineral and Bone Disorder
Calcium
Kidney
Hypoparathyroidism
Radioligand Assay
Parathyroid Glands
Primary Hyperparathyroidism
Kidney Transplantation
Chronic Kidney Failure
Thyroid Gland
Ions
Diet
dihydroxy-vitamin D3

ASJC Scopus subject areas

  • Endocrinology

Cite this

Haussler, M. R., Baylink, D. J., Hughes, M. R., Brumbaugh, P. F., Wergedal, J. E., Shen, F. H., ... McCain, T. A. (1976). The assay of 1alpha,25-dihydroxyvitamin D3: physiologic and pathologic modulation of circulating hormone levels. Clinical Endocrinology, 5 Suppl.

The assay of 1alpha,25-dihydroxyvitamin D3 : physiologic and pathologic modulation of circulating hormone levels. / Haussler, Mark R; Baylink, D. J.; Hughes, M. R.; Brumbaugh, P. F.; Wergedal, J. E.; Shen, F. H.; Nielsen, R. L.; Counts, S. J.; Bursac, K. M.; McCain, T. A.

In: Clinical Endocrinology, Vol. 5 Suppl, 1976.

Research output: Contribution to journalArticle

Haussler, MR, Baylink, DJ, Hughes, MR, Brumbaugh, PF, Wergedal, JE, Shen, FH, Nielsen, RL, Counts, SJ, Bursac, KM & McCain, TA 1976, 'The assay of 1alpha,25-dihydroxyvitamin D3: physiologic and pathologic modulation of circulating hormone levels.', Clinical Endocrinology, vol. 5 Suppl.
Haussler, Mark R ; Baylink, D. J. ; Hughes, M. R. ; Brumbaugh, P. F. ; Wergedal, J. E. ; Shen, F. H. ; Nielsen, R. L. ; Counts, S. J. ; Bursac, K. M. ; McCain, T. A. / The assay of 1alpha,25-dihydroxyvitamin D3 : physiologic and pathologic modulation of circulating hormone levels. In: Clinical Endocrinology. 1976 ; Vol. 5 Suppl.
@article{5f3660b1ef974d1abc3b0e687588f2c7,
title = "The assay of 1alpha,25-dihydroxyvitamin D3: physiologic and pathologic modulation of circulating hormone levels.",
abstract = "A sensitive radioreceptor assay for 1alpha,25-dihydroxyvitamin D3 (1alpha,25-(OH)2D3) is utilized to quantitate the circulating concentration of this sterol in experimental animals and humans. When weanling rats are grown for 2 weeks on low calcium or low phosphate diets, limited availability of either ion elicits a five-fold increase in the plasma level of 1alpha,25-(OH)2D3. The enhancement of 1alpha,25-(OH)2D3 in calcium deficiency is dependent upon the presence of the parathyroid and/or thyroid glands, which is consistent with parathyroid hormone (PTH) mediation of this effect. In contrast, the response to phosphate deficiency is independent of these glands and may result from a direct action of low phosphate on the renal synthesis of 1alpha,25-(OH)2D3. Studies in humans indicate that the normal level of 1alpha,25-(OH)2D is 2.1--4.5 ng/100 ml plasma. Patients with chronic renal failure have markedly lower circulating 1alpha,25-(OH)2D and this kidney hormone is undetectable in anephric subjects, but returns to normal within 1 day after successful renal transplantation. Hypoparathyroidism and pseudohypoparathyroidism are associated with reduced plasma 1alpha,25-(OH)2D while patients with primary hyperparathyroidism have significantly elevated sterol hormone levels. Thus, from measurements in rats and humans, it appears that circulating 1alpha,25-(OH)2D3 is regulated by PTH and/or phosphate and that abnormal plasma 1alpha,25-(OH)2D3 is a part of the pathophysiology of renal osteodystrophy and parathyroid disorders.",
author = "Haussler, {Mark R} and Baylink, {D. J.} and Hughes, {M. R.} and Brumbaugh, {P. F.} and Wergedal, {J. E.} and Shen, {F. H.} and Nielsen, {R. L.} and Counts, {S. J.} and Bursac, {K. M.} and McCain, {T. A.}",
year = "1976",
language = "English (US)",
volume = "5 Suppl",
journal = "Clinical Endocrinology",
issn = "0300-0664",
publisher = "Wiley-Blackwell",

}

TY - JOUR

T1 - The assay of 1alpha,25-dihydroxyvitamin D3

T2 - physiologic and pathologic modulation of circulating hormone levels.

AU - Haussler, Mark R

AU - Baylink, D. J.

AU - Hughes, M. R.

AU - Brumbaugh, P. F.

AU - Wergedal, J. E.

AU - Shen, F. H.

AU - Nielsen, R. L.

AU - Counts, S. J.

AU - Bursac, K. M.

AU - McCain, T. A.

PY - 1976

Y1 - 1976

N2 - A sensitive radioreceptor assay for 1alpha,25-dihydroxyvitamin D3 (1alpha,25-(OH)2D3) is utilized to quantitate the circulating concentration of this sterol in experimental animals and humans. When weanling rats are grown for 2 weeks on low calcium or low phosphate diets, limited availability of either ion elicits a five-fold increase in the plasma level of 1alpha,25-(OH)2D3. The enhancement of 1alpha,25-(OH)2D3 in calcium deficiency is dependent upon the presence of the parathyroid and/or thyroid glands, which is consistent with parathyroid hormone (PTH) mediation of this effect. In contrast, the response to phosphate deficiency is independent of these glands and may result from a direct action of low phosphate on the renal synthesis of 1alpha,25-(OH)2D3. Studies in humans indicate that the normal level of 1alpha,25-(OH)2D is 2.1--4.5 ng/100 ml plasma. Patients with chronic renal failure have markedly lower circulating 1alpha,25-(OH)2D and this kidney hormone is undetectable in anephric subjects, but returns to normal within 1 day after successful renal transplantation. Hypoparathyroidism and pseudohypoparathyroidism are associated with reduced plasma 1alpha,25-(OH)2D while patients with primary hyperparathyroidism have significantly elevated sterol hormone levels. Thus, from measurements in rats and humans, it appears that circulating 1alpha,25-(OH)2D3 is regulated by PTH and/or phosphate and that abnormal plasma 1alpha,25-(OH)2D3 is a part of the pathophysiology of renal osteodystrophy and parathyroid disorders.

AB - A sensitive radioreceptor assay for 1alpha,25-dihydroxyvitamin D3 (1alpha,25-(OH)2D3) is utilized to quantitate the circulating concentration of this sterol in experimental animals and humans. When weanling rats are grown for 2 weeks on low calcium or low phosphate diets, limited availability of either ion elicits a five-fold increase in the plasma level of 1alpha,25-(OH)2D3. The enhancement of 1alpha,25-(OH)2D3 in calcium deficiency is dependent upon the presence of the parathyroid and/or thyroid glands, which is consistent with parathyroid hormone (PTH) mediation of this effect. In contrast, the response to phosphate deficiency is independent of these glands and may result from a direct action of low phosphate on the renal synthesis of 1alpha,25-(OH)2D3. Studies in humans indicate that the normal level of 1alpha,25-(OH)2D is 2.1--4.5 ng/100 ml plasma. Patients with chronic renal failure have markedly lower circulating 1alpha,25-(OH)2D and this kidney hormone is undetectable in anephric subjects, but returns to normal within 1 day after successful renal transplantation. Hypoparathyroidism and pseudohypoparathyroidism are associated with reduced plasma 1alpha,25-(OH)2D while patients with primary hyperparathyroidism have significantly elevated sterol hormone levels. Thus, from measurements in rats and humans, it appears that circulating 1alpha,25-(OH)2D3 is regulated by PTH and/or phosphate and that abnormal plasma 1alpha,25-(OH)2D3 is a part of the pathophysiology of renal osteodystrophy and parathyroid disorders.

UR - http://www.scopus.com/inward/record.url?scp=18344400802&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=18344400802&partnerID=8YFLogxK

M3 - Article

C2 - 212227

AN - SCOPUS:18344400802

VL - 5 Suppl

JO - Clinical Endocrinology

JF - Clinical Endocrinology

SN - 0300-0664

ER -